History of DCA in the Treatment of Brain Cancer

DCA or Sodium Dichloroacetate which is the sodium derivative of dichloroacetate is a fairly inexpensive chemical complex that has shown quite clearly some potential as a substitute cancer treatment. This is according to researchers in Canada at the University of Alberta. Its safety has been assessed by researchers at the University of Florida. It has been used in numerous trials with individuals suffering from brain cancer or glioblastoma.

American National Cancer Institute

The American National Cancer Institute describes DCA as the sodiumderivative of Dichloroacetic acid that has prospective antineoplastic action. The ion of dichloroacetate constrains pyruvate dehydrogenase kinase, and results in the inhibition of glycolysis as well as a reduction in the production of lactate. This agent might encourage apoptosis in cells of cancer by restoring the normal mitochondrial-induced apoptotic signaling.

Image result for History of DCA in the Treatment of Brain Cancer

Restores mitochondria

Dr. Michelakis, professor at the University of Alberta has further shown that DCA can restate mitochondria turning them back on and allowing the cells of cancer to temporarily return to ‘normal’ when it recognizes there is a problem and helps with cell death. He has found that DCA can cause increased death of cancer cells in almost every type of cancer and it also can achieve this by the simple addition of this compound to the water you drink. Of special interest is Dr. Michelakis preliminary work with cancer of the brain.

Five patients with brain cancer

In 2010, five patients with cancer of the brain (glioblastoma) as well as dismal prognosis were put on a treatment of DCA and there was great prospective in the results.

Selling on internet

Very suddenly, DCA was put for sell on many internet sites. The Anticancer Fund in the United States appointed two skilled researchers – Dr. Erin Dunbar and Dr. Peter Stacpoole from the University of Florida to conduct phase 1 clinical trial among 15 subjects with tumors of the brain to discover dosage levels and any probable side-effects. They found that doses depend on the personal ability of each individual to breakdown the dca. This was not a trial to study how effective DCA is. But this research lasted almost 5 years. Now, there are some groups that are trying to find funding to develop DCA and they will then continue with any trials.